Scientific Company Directory
The latest research, products, and discoveries from the science industry’s leading companies and company divisions.
NEW
Scientific Products
From innovative tools to essential equipment and supplies, find everything you need to advance your research on our new Scientific Products page.
Search Scientific Products
Nicoya is a pioneering company at the forefront of democratizing scientific exploration through groundbreaking advancements in microfluidics and nanotechnology. Committed to making cutting-edge label-free surface plasmon resonance technology accessible to scientists across disciplines, Nicoya specializes in miniaturizing biomolecular binding analysis, with the aim to simplify experiments by automating user operation, reducing sample sizes by more than 100-fold, and eliminating bulky and complex instrumentation, ultimately providing researchers with cost-effective and easy-to-use tools. At Nicoya, our commitment to making technology more accessible drives us to empower scientists globally, fostering a new era of exploration and innovation.
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.
NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, with modern and simple technologies for cell based assays. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF's technology before introducing the WOLF to early adopters. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts. We are backed by Illumina Ventures, FusionX Ventures, Anzu Partners, Agilent Technologies, Vertical Ventures (Highlander Fund and Triton Fund) and other private investors.
NMI TT Pharmaservices is an established provider of non-clinical contract research for protein profiling services, custom cell services, and electrophysiology services. The company has a long-standing CRO track record with numerous small, medium and large pharma and biotech companies worldwide. The services are accessible through direct contracts or Master Service Agreements (MSAs), or immediately via online marketplaces Scientist.com and ScienceExchange.
On behalf of the Board of Directors and members, I thank you in advance for your interest in the New Jersey Association for Biomedical Research (NJABR). As one of the best advocacy organizations representing the biomedical research community in the country, we look forward to the opportunity to partner with you and work to advance human and animal health together. Members utilize our services and benefits in many different ways, but NJABR is known for the development of internationally recognized educational programming and legal and legislative monitoring. NJABR is not afraid to address the controversial issues that impact the research community and we advocate tirelessly to increase the understanding of the critical role and value of animal research. We advocate for continued access to all biomedical research models and to ensure New Jersey, and the country as a whole, become better places to conduct research.
The North American 3Rs Collaborative (NA3RsC) is a nonprofit organization whose mission is to advance science, innovation, and research animal welfare. We facilitate collaborative opportunities to refine, reduce, and replace animals in research. We are unique in growing partnerships between academics, pharmaceutical companies, vendors, technology providers, contract research organizations, government organizations, regulatory agents, and other non-profits. This diversity is reflected in our organizational leadership. Such partnerships are essential for the development and implementation of the 3Rs. We aim to be a leading authority on the 3Rs in North America & globally.
NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on enabling researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.
Neutec Group provides cost effective Instrument and Automation Solutions which enhance the productivity of the Micro and Biotech Labs. Our products are distinguished by innovative design, durability, reliability, and value - the same qualities we look for when selecting partners. We integrate the products we represent with accessories, interface them with computers and printers, and build complete laboratory solutions to meet your specific needs. Some of our products include: Agar & Tube Fillers, Media Preparators, our innovative Spiral Plater, Automatic Colony Counters, Petri Labeler, Water Activity Meters, Multi Spectral imaging texture/color analyzer.
NuProbe takes a multi-platform approach to apply its breakthrough technologies in genomics research to enable diseases to be detected, treated, and cured at early stages for better outcomes with lower costs.
Founded in 2016 and building on scientific findings licensed from the Wyss Institute at Harvard and Rice University, NuProbe is a privately held company with facilities in the US (Houston, TX) and China (Shanghai). The company has assembled an executive team of industry veterans, world-renowned scientists, and entrepreneurs.
Simply put, that's our mission: providing innovative cannabis products to all customers. From our sweet-and-sour THC and CBD gummies to our line of affordable inhalers, each packed with pure THC liquid for particulate delivery, we work to help enthusiasts and cannabis patients relax, unwind, and Njoy life.
Nicoya is a Canadian biotechnology company specializing in innovative biosensor technology for label-free biomolecular characterization. In their mission to improve human life, they empower researchers with affordable and user-friendly solutions that maximize their access to high-quality data and advance their understanding of human diseases. With their world-class expertise in nanotechnology and microfluidics, Nicoya is now helping hundreds of scientists succeed in over 40 countries. Visit https://nicoyalife.com/ to learn more.
Navitar designs, develops and manufactures innovative optical solutions for clients and enterprises across the globe. Solutions include complete optomechanical and optoelectronic assembly and sub-assembly systems. Our products range from high magnification motorized zoom imaging systems to fisheye projection lenses used in a wide variety of industries including Life Sciences, Industrial Imaging, Microscopy and Projection.
The key to our success is our consultative approach to solving complex optical problems through inventive design techniques, the precision at which product is assembled, and the efficiency in which projects move through our business units.
The brain is the most complex and least understood organ in the body. NanoSomiX, Inc. is at the forefront in establishing an entirely new class of non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using Brain Derived Exosomes (BDE). We are interested in working collaboratively with researchers worldwide to use our blood-based assay technology to further biomarker exploration in neurodegenerative diseases.
Exosomes are extremely small, membrane-bound vesicles produced by cells throughout the body. NanoSomiX is specifically focused on BDEs - exosomes produced by various brain cell populations. A characteristic of BDEs is that they carry brain-produced biomarkers that relate to brain function. With a simple blood draw, pathologic forms or modulation of certain biomarkers can be assessed by our technology. This biomarker assessment can provide needed information about the health and current status of the different brain cell types.
Our laboratory is working with both academic researchers and commercial companies to support ongoing research into biomarkers associated with various neurologic diseases and neurotrauma. Much of our contract work involves studies to confirm the detection of specific biomarkers of interest, and to design protocols for diagnostic or monitoring applications. Working within a CLIA laboratory environment, we can provide a blood-based assay that is repeatable, cost effective and fits easily into a routine diagnostic or research environment.
Our proprietary exosome isolation technology is covered by a recently granted patent, with 5 additional patent applications in process to cover various aspects of BDE processing and marker application. Using BDEs to explore clinical applications in neurodegenerative diseases is supported by several peer-reviewed publications. We are ready to work with you to help move your important biomarker projects forward.
